Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG-Cisplatin Nanoprobes for Fluorescence-Guided Liver Resection in HCC
NCT07295262Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICG-Cisplatin nanoprobe in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Recurrence-Free Survival at 3 years and Rate of Successful Fluorescence Staining at Day 0. Started Jan 2026; status: recruiting.
02
Drugs
ICG-Cisplatin nanoprobe
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07295262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295262.